{
  "abstract": "DNA mismatch repair deficiency has been identified as a biomarker that strongly correlates with tumor response to anti-programmed cell death protein-1 (PD-1) checkpoint blockade therapy in the metastatic setting. In a promising Phase 2 study published in the New England Journal of Medicine, Cercek et al demonstrate that PD-1 checkpoint blockade also has potential in the neoadjuvant setting and may eliminate the need for surgical intervention. These results offer great hope to patients with a variety of solid malignancies because those who experience complete clinical responses may be able to safely choose non-operative management to preserve organ function and minimize side effects associated with surgery.",
  "authors": [
    {
      "affiliations": [
        "Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA"
      ],
      "name": "Kristin G Anderson"
    },
    {
      "affiliations": [
        "University of California Los Angeles, Los Angeles, California, USA"
      ],
      "name": "Antoni Ribas"
    }
  ],
  "title": "Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors",
  "uid": "a679b2c2-6729-533a-a6dd-262cba676531"
}